Evidence map›Paper›PMID 30022351›Full record

ReviewStem cell reviews and reports2018

Elevated Numbers of Circulating Very Small Embryonic-Like Stem Cells (VSELs) and Intermediate CD14++CD16+ Monocytes in IgA Nephropathy.

Andrzej Eljaszewicz, Katarzyna Kleina, Kamil Grubczak, Urszula Radzikowska, Paula Zembko, Paulina Kaczmarczyk, Marlena Tynecka, Karolina Dworzanczyk, Beata Naumnik, Marcin Moniuszko

Open access · hybridAbstract readReview
In one paragraph

Review in Stem cell reviews and reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Andrzej EljaszewiczDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Bialystok, Poland. Andrzej.Eljaszewicz@umb.edu.pl.
Katarzyna Kleina1st Department of Nephrology with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
Kamil GrubczakDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Bialystok, Poland.
Urszula RadzikowskaDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Bialystok, Poland.
Paula ZembkoDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Bialystok, Poland.
Paulina KaczmarczykDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Bialystok, Poland.
Marlena TyneckaDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Bialystok, Poland.
Karolina Dworzanczyk1st Department of Nephrology with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
Beata Naumnik1st Department of Nephrology with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
Marcin MoniuszkoDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Bialystok, Poland. Marcin.Moniuszko@umb.edu.pl.
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgA nephropathy (IgAN) is recognized as most frequent form of primary glomerulonephritis worldwide. IgAN is associated with renal degradation occurring due to irreversible pathological changes leading to glomerulosclerosis and interstitial fibrosis. It remains poorly understood whether and to what extent these changes are followed by the activation of regenerative mechanisms. Therefore, in this study we aimed to evaluate regenerative potential of IgAN patients by quantitating the frequencies of several stem cell types, namely circulating very small embryonic-like stem cells (VSELs), hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs) as well as different monocyte subsets with varying maturation and angiopoietic potential. Moreover, we analyzed whether changes in stem cell and monocyte frequencies were related to alterations of several chemotactic factors (stromal derived-factor (SDF-1), angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2)) and a marker of monocyte/macrophage activation, namely soluble form of CD163 receptor (sCD163). We showed that IgAN patients presented with enhanced levels of VSELs, but not other stem cell types. We also demonstrated significantly elevated numbers of intermediate monocytes known for their M2-like properties as well as high angiopoietic potential and CD163 expression. This finding was accompanied by detection of elevated sCD163 plasma levels in IgAN patients. Taking together, we demonstrated here that IgAN is associated with selective mobilization of VSELs and increased maturation of monocytes towards M2-like and angiopoietic phenotype. These findings contribute to better understanding of the role of regenerative mechanisms in the pathogenesis of chronic inflammation in the course of IgAN.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenChemokine CXCL12Embryonic Stem CellsEndothelial Progenitor CellsGlomerulonephritisGlomerulonephritis, IGAHematopoietic Stem CellsHumansImmunoglobulin ALipopolysaccharide ReceptorsPeripheral Blood Stem CellsReceptors, Cell SurfaceReceptors, IgGAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenChemokine CXCL12CXCL12 protein, humanImmunoglobulin ALipopolysaccharide ReceptorsReceptors, Cell SurfaceReceptors, IgGAng-1Ang-2EPCsHSCsIgA nephropathyMonocytesRegenerationsCD163SDF-1VSELs

Identifiers

PMID30022351
PMCPMC6132770
OpenAlexW2884962945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.